Atlas DiscoveryYC S26 landing page report.
← Back to YC S26

Your landing page’s weakest score is CTA.

Fix CTA

Score over time

70605040Insilico Medicine 54 on Jun 16 (Wayback)Insilico Medicine 55 on Jun 27 (Wayback)Insilico Medicine 56 on Jul 15 (Wayback)Insilico Medicine 56 on Jul 26 (Wayback)Insilico Medicine 56 on Aug 10 (Wayback)Insilico Medicine 57 on Sep 9 (Wayback)Insilico Medicine 54 on Sep 22 (Live)Recursion 63 on Jun 26 (Wayback)Recursion 62 on Jul 7 (Wayback)Recursion 64 on Jul 22 (Wayback)Recursion 50 on Aug 10 (Wayback)Recursion 50 on Aug 27 (Wayback)Recursion 53 on Sep 11 (Wayback)Recursion 66 on Sep 20 (Live)Every Cure 57 on May 19 (Wayback)Every Cure 54 on Jun 11 (Wayback)Every Cure 55 on Jun 19 (Wayback)Every Cure 55 on Jul 11 (Wayback)Every Cure 56 on Jul 21 (Wayback)Every Cure 56 on Aug 31 (Wayback)Every Cure 46 on Sep 20 (Live)Healx 47 on May 9 (Wayback)Healx 50 on May 21 (Wayback)Healx 48 on Jun 9 (Wayback)Healx 50 on Jun 19 (Wayback)Healx 48 on Jul 24 (Wayback)Healx 47 on Sep 17 (Wayback)Healx 46 on Sep 20 (Live)Pharos iBio / Standigm 50 on Sep 23 (Live)Atlas Discovery 54 on Sep 20 (Live)Sep 20

CTA

44Poor

Copy, size, verb, cost-feel — does the primary CTA earn the click?

blog
Atlas Discovery
Recursion
Every Cure

Problems

  • no button or input anywhere
  • primary action is a text link
  • routes to reading, not converting
  • conversion links buried in footer

Trust

48Poor

Proof that the product is real, competent, and safe to try.

Atlas Discovery
Insilico Medicine
Recursion
Trust read
Atlas Discovery"Backed by — YCombinator" table row
Insilico MedicinePipeline table rows showing "Out-licensed to Exelixis" and "Out-licensed to Menarini" with Phase I–III progress bars and
RecursionUnlocking the First Neuroscience Target for the Recursion and Genentech Collaboration
Every CurePhotograph of a clinician consulting with a hospital patient behind the hero headline
HealxNo visible trust signal identified.
Pharos iBio / StandigmNo visible trust signal identified.

Information hierarchy

58Fair

Does the design help or inhibit what the page is trying to say?

Information hierarchy annotations on the desktop capture123
  1. Footer link row — The only actionable paths (Contact, Join us) sit in the footer at the same weight as social exits — no primary CTA exists anywhere above them.
  2. Inline blog link — The sole in-body link routes convinced visitors away to a blog instead of toward contact or hiring.
  3. LinkedIn Twitter links — Social exits share the same row and weight as the conversion links, splitting the little click attention the fold has.

Value props

58Fair

Title, subtitle, hero — do they sell the product's true value?

Atlas Discovery’s headline undersellsAtlas DiscoveryAn AI-native pharma company pushing the economic frontier of medicine. We build autonomous agents that repurpose drugs for new diseases and run clinical trials efficiently.

Working

  • Names real mechanism: drug repurposing
  • Research + YC proof points in fold
  • Clean, credible academic tone

Could improve

  • 'Economic frontier' opener is abstract
  • No numbers on speed, cost, or scale
  • Wave graphic decorates, shows nothing

Mobile web

62Fair

The phone experience as a first-class citizen.

Mobile web annotations on the mobile capture12
  1. Blog text link — The only in-fold action is a small inline hyperlink — no thumb-sized primary CTA exists on the page.
  2. Footer contact links — "Contact" and "Join us" are tiny text links buried below a full screen of decorative art.